Literature DB >> 25676798

Tropisetron ameliorates early diabetic nephropathy in streptozotocin-induced diabetic rats.

Anita Barzegar-Fallah1, Houman Alimoradi, Firouzeh Asadi, Ahmad Reza Dehpour, Mojgan Asgari, Massoumeh Shafiei.   

Abstract

It has been well established that oxidative stress and inflammation are involved in the pathogenesis of diabetic nephropathy. It has been shown that tropisetron exerts anti-inflammatory and immunomodulatory properties. The current study was designed to investigate protective effects of tropisetron on early diabetic nephropathy in streptozotocin-induced diabetic rats. Rats were divided into six groups: (i) untreated diabetic (streptozotocin group); (ii) untreated control; (iii) diabetic rats treated with tropisetron (3 mg/kg); (iv) normal rats treated with tropisetron (3 mg/kg); (v) diabetic rats treated with granisetron (3 mg/kg); and (vi) normal rats treated with granisetron (3 mg/kg); rats began receiving treatment at the time of diabetes induction for 2 weeks. At the termination of the experiments, bodyweight, kidney index, urinary albumin excretion, and glomerular filtration rate were measured. The levels of oxidative stress markers and tumour necrosis factor-α were also determined. Streptozotocin-treated animals showed significant loss of bodyweight and renal enlargement and dysfunction. Diabetic rats also exhibited an increase in malondialdehyde along with a significant decrease in glutathione, superoxide dismutase activity, and catalase activity. Furthermore, the diabetic animals demonstrated a significant rise in renal cortical, urinary tumour necrosis factor-α, and urinary albumin excretion. Both granisetron and tropisetron decreased blood glucose in diabetic animals, but this decrease was not significant for granisetron. Treatment with tropisetron, but not granisetron, prevented increases in oxidative stress and tumour necrosis factor-α, decreased urinary cytokine excretion and albuminuria, and improved renal morphological damage. In conclusion, the present study suggests that tropisetron may be a protective agent in early diabetic nephropathy, and its action is mediated, at least in part, by anti-oxidative and anti-inflammatory mechanisms that appear to be independent of the 5-HT3 receptor.
© 2015 Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  diabetic nephropathy; oxidative stress; renal function; tropisetron; tumour necrosis factor-α

Mesh:

Substances:

Year:  2015        PMID: 25676798     DOI: 10.1111/1440-1681.12373

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  9 in total

1.  The effect of tropisetron on peripheral diabetic neuropathy: possible protective actions against inflammation and apoptosis.

Authors:  Amir Mohammad Ghazipour; Bagher Pourheydar; Roya Naderi
Journal:  Cell Stress Chaperones       Date:  2022-08-16       Impact factor: 3.827

2.  Anti-diabetic and renoprotective effects of aliskiren in streptozotocin-induced diabetic nephropathy in female rats.

Authors:  Amal M Mahfoz; Hekma A Abd El-Latif; Lamiaa A Ahmed; Nahed M Hassanein; Afaf A Shoka
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-09       Impact factor: 3.000

3.  The effect of tropisetron on oxidative stress, SIRT1, FOXO3a, and claudin-1 in the renal tissue of STZ-induced diabetic rats.

Authors:  Mahrokh Samadi; Shiva Gholizadeh-Ghaleh Aziz; Roya Naderi
Journal:  Cell Stress Chaperones       Date:  2020-10-12       Impact factor: 3.667

4.  Association of 5-Hydroxytryptamine 3 Receptor Antagonists With the Prognosis of Liver Failure.

Authors:  Yuting Chen; Jingkang Sun; Xiude Fan; Xiaoyun Wang; Lu Zeng; Xiaoge Zhang; Kun Zhang; Na Li; Qunying Han; Zhengwen Liu
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

5.  Effects of α lipoic acid combined with olmesartan medoxomil on blood glucose and oxidation indicators in patients with diabetic nephropathy: A protocol for a parallel, randomized, double-blind, controlled clinical trial.

Authors:  Shengfu Jiao; Yuxia Dong; Xiang Chang; Yanan Wu; Haifeng Li
Journal:  Medicine (Baltimore)       Date:  2022-04-29       Impact factor: 1.817

Review 6.  Serotonin and Its Receptor as a New Antioxidant Therapeutic Target for Diabetic Kidney Disease.

Authors:  Yu Yang; Hui Huang; Zheng Xu; Jun-Kai Duan
Journal:  J Diabetes Res       Date:  2017-08-08       Impact factor: 4.011

Review 7.  Tapping into 5-HT3 Receptors to Modify Metabolic and Immune Responses.

Authors:  Helen Irving; Ilona Turek; Christine Kettle; Nor Yaakob
Journal:  Int J Mol Sci       Date:  2021-11-02       Impact factor: 5.923

Review 8.  Indole-Based Small Molecules as Potential Therapeutic Agents for the Treatment of Fibrosis.

Authors:  Rui Qin; Qian Zhao; Bo Han; Hong-Ping Zhu; Cheng Peng; Gu Zhan; Wei Huang
Journal:  Front Pharmacol       Date:  2022-02-16       Impact factor: 5.810

9.  Early Postoperative Ondansetron Exposure is Associated with Reduced 90-Day Mortality in Patients Undergoing Cardiac Surgery.

Authors:  Dexin Xiong; Chao Xiong
Journal:  Front Surg       Date:  2022-06-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.